195 related articles for article (PubMed ID: 22570059)
1. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
[TBL] [Abstract][Full Text] [Related]
2. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.
Shimamura T; Fujisawa T; Husain SR; Joshi B; Puri RK
Clin Cancer Res; 2010 Jan; 16(2):577-86. PubMed ID: 20068108
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
Kawakami K; Terabe M; Kioi M; Berzofsky JA; Puri RK
Clin Cancer Res; 2006 Aug; 12(15):4678-86. PubMed ID: 16899618
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of the alpha2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells.
He H; Xu J; Nelson PS; Marshall FF; Chung LW; Zhau HE; He D; Wang R
Prostate; 2010 Jun; 70(9):993-1001. PubMed ID: 20166133
[TBL] [Abstract][Full Text] [Related]
6. An IL13Rα2 peptide exhibits therapeutic activity against metastatic colorectal cancer.
Bartolomé RA; Jaén M; Casal JI
Br J Cancer; 2018 Oct; 119(8):940-949. PubMed ID: 30318506
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.
Liu-Chittenden Y; Jain M; Kumar P; Patel D; Aufforth R; Neychev V; Sadowski S; Gara SK; Joshi BH; Cottle-Delisle C; Merkel R; Yang L; Miettinen M; Puri RK; Kebebew E
Cancer Med; 2015 Jul; 4(7):1060-8. PubMed ID: 25767039
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
[TBL] [Abstract][Full Text] [Related]
9. IL13 Fused
Uludağ D; Karakaş N
Anticancer Res; 2021 Jul; 41(7):3471-3480. PubMed ID: 34230142
[TBL] [Abstract][Full Text] [Related]
10. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
[TBL] [Abstract][Full Text] [Related]
11. Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy.
Joshi BH; Leland P; Calvo A; Green JE; Puri RK
Cancer Res; 2008 Nov; 68(22):9311-7. PubMed ID: 19010904
[TBL] [Abstract][Full Text] [Related]
12. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.
Stern LA; Gholamin S; Moraga I; Yang X; Saravanakumar S; Cohen JR; Starr R; Aguilar B; Salvary V; Hibbard JC; Kalbasi A; Shepphird JK; O'Hearn J; Garcia KC; Brown CE
Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2112006119. PubMed ID: 35939683
[TBL] [Abstract][Full Text] [Related]
13. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
14. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
15. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
[TBL] [Abstract][Full Text] [Related]
16. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-13 receptor α2 is a novel marker and potential therapeutic target for human melanoma.
Okamoto H; Yoshimatsu Y; Tomizawa T; Kunita A; Takayama R; Morikawa T; Komura D; Takahashi K; Oshima T; Sato M; Komai M; Podyma-Inoue KA; Uchida H; Hamada H; Fujiu K; Ishikawa S; Fukayama M; Fukuhara T; Watabe T
Sci Rep; 2019 Feb; 9(1):1281. PubMed ID: 30718742
[TBL] [Abstract][Full Text] [Related]
18. A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression.
Wang T; Subramanian C; Blagg BSJ; Cohen MS
Surgery; 2020 Jan; 167(1):233-240. PubMed ID: 31561992
[TBL] [Abstract][Full Text] [Related]
19. Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies.
Mahadev V; Starr R; Wright SL; Martinez C; Jensen MC; Barish ME; Forman SJ; Brown CE
PLoS One; 2014; 9(5):e95123. PubMed ID: 24787244
[TBL] [Abstract][Full Text] [Related]
20. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
